Evidence map›Paper›PMID 32529797›Full record

ArticleCancer medicine2020

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.

Mohammed A Alghamdi, Carla P Amaro, Richard Lee-Ying, Hao-Wen Sim, Haider Samwi, Kelvin K Chan, Jennifer J Knox, Yoo-Joung Ko, Mina Swiha, Eugene Batuyong and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Investigating Real-World Tolerance and Dose Reductions of Oncology Multikinase Inhibitors in a VA Population.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mohammed A AlghamdiTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Carla P AmaroTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.ORCID 0000-0001-5533-4786
Richard Lee-YingTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Hao-Wen SimPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Haider SamwiSt. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Kelvin K ChanSunnybrook Odette Cancer Centre, Toronto, ON, Canada.
Jennifer J KnoxPrincess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Yoo-Joung KoSunnybrook Odette Cancer Centre, Toronto, ON, Canada.
Mina SwihaUniversity of Western Ontario, London, ON, Canada.
Eugene BatuyongTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Adriana RomagninoSunnybrook Odette Cancer Centre, Toronto, ON, Canada.
Winson Y CheungTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
Vincent C TamTom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.ORCID 0000-0001-8732-0530
Hepatocellular Carcinoma - Cancer Health Outcomes Research Database (HCC - CHORD) Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSorafenib has been shown to improve survival in patients with advanced hepatocellular carcinoma (HCC), however, full dose can be difficult to tolerate. The aim of this study was to determine whether sorafenib starting dose and mean dose intensity affect survival.

methodsPatients treated with sorafenib for HCC from January 2008 to July 2016 in several Canadian provinces were included and retrospectively analyzed. The primary end point was overall survival (OS) of patients starting on sorafenib full dose compared to reduced dose. Secondary analysis compared OS with different mean dose-intensity groups. Survival outcomes were assessed with Kaplan-Meier curves and Cox proportional hazards models. A propensity score analysis was performed to account for treatment bias and confounding.

resultsOf 681 patients included, sorafenib was started at full dose in 289 patients (42%). Median survival for starting full and reduced dose was 9.4 months and 8.9 months (P = .15) respectively. After propensity score matching and adjusting for potential confounders there was still no difference in survival (HR 0.8, 95% CI, 0.61-1.06, P = .12). Almost half of the patients (45%) received a dose intensity < 50%. Median survival for mean dose intensity > 75%, 50%-75%, and < 50% were 9.5 months, 12.9 months, and 7.1 months (P = .005) respectively. In multivariable models, starting dose(HR 1.16, 95% CI 0.93-1.44, P = .180) and mean dose intensity were not associated with survival.

conclusionsStarting HCC patients on a reduced dose of sorafenib compared to full dose may not compromise survival. Mean dose-intensity of sorafenib may also not affect survival.

Indexed as

Antineoplastic AgentsCanadaCarcinoma, HepatocellularFemaleHumansLiver NeoplasmsMaleMiddle AgedSorafenibTreatment OutcomeAntineoplastic AgentsSorafenibdiscontinuation ratedose intensityhepatocellular carcinomasorafenibstarting dose

Identifiers

PMID32529797
PMCPMC7367626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.